Skip to main content

Table 4 Comparison of immunogenicity of 2010-2011 influenza vaccines against H1N1 pdm09 between infection-primed group and vaccine-primed group in the split and subunit vaccine group among children 9-18 years of age

From: The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study

  IP (n = 32) VP (n = 145) P value
Split   17 57  
Mean age   12.81 (±2.44) 11.76 (±2.01) 0.077
Seroprotection (%) Baseline 70.59 (12/17) 52.63 (30/57) 0.098
1 month 94.12 (16/17) 75.44 (43/57) 0.001
6 months 86.67 (13/15) 76.00 (38/50) 0.038
Seroconversion (%)   64.71 (11/17) 38.60 (22/57) 0.001
GMT (95 % CI) Baseline 35.39 (26.93–43.86) 30.61 (23.99–37.24) 0.644
1 month 250.56 (138.16–362.95) 77.13 (66.37–87.90) 0.004
6 months 139.29 (94.10–184.47) 64.09 (53.03–75.14) 0.019
Subunit   15 88  
Mean age   12.30 (±2.67) 12.74 (±2.57) 0.544
Seroprotection (%) Baseline 73.33 (11/15) 60.23 (53/88) 0.345
1 month 93.33 (14/15) 73.86 (65/88) 0.022
6 months 62.5 (5/8) 45.68 (37/81) 0.369
Seroconversion (%)   73.33 (11/15) 37.50 (33/88) 0.011
GMT (95 % CI) Baseline 60.63 (36.22–85.04) 28.28 (23.98–32.59) 0.015
1 month 242.51 (158.95–326.08) 65.70 (51.58–79.82) 0.002
6 months 56.57 (10.48–102.66) 29.05 (23.28–34.82) 0.166